Evidence map›Paper›PMID 30389984›Full record

ArticleScientific reports2018

Antimicrobial Activities and Mechanisms of Magnesium Oxide Nanoparticles (nMgO) against Pathogenic Bacteria, Yeasts, and Biofilms.

Nhu-Y Thi Nguyen, Nathaniel Grelling, Cheyann Lee Wetteland, Romeo Rosario, Huinan Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 1 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 1 synthesis or guideline pooled it, 328 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nhu-Y Thi NguyenMicrobiology Graduate Program, University of California, Riverside, CA, 92521, USA.
Nathaniel GrellingDepartment of Bioengineering, University of California, Riverside, CA, 92521, USA.
Cheyann Lee WettelandDepartment of Bioengineering, University of California, Riverside, CA, 92521, USA.
Romeo RosarioDepartment of Bioengineering, University of California, Riverside, CA, 92521, USA.
Huinan LiuMicrobiology Graduate Program, University of California, Riverside, CA, 92521, USA. huinan.liu@ucr.edu.ORCID http://orcid.org/0000-0001-9366-6204
University of California, Riverside · US

Funding

Antimicrobial Biodegradable Bone Graft for Craniofacial/Maxillofacial ApplicationR44DE023287 · NIDCR · N2 BIOMEDICAL, LLC · PI BURNS, JASON E · 2016 to 2017
$1.2M
Antibacterial Biocompatible Bioresorbable Alloys for Musculoskeletal ImplantsR03AR069373 · NIAMS · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI LIU, HUINAN HANNAH · 2016 to 2018
$206k
Antimicrobial Biodegradable Bone Graft for Craniofacial/Maxillofacial ApplicationR43DE023287 · NIDCR · N2 BIOMEDICAL, LLC · PI ASLANI, ARASH · 2013 to 2013
$203k
NIAMS NIH HHS R03 AR069373NIDCR NIH HHS R43 DE023287NIDCR NIH HHS R44 DE023287
6 · The paper itself

Abstract

Magnesium oxide nanoparticle (nMgO) is a light metal based antimicrobial nanoparticle that can be metabolized and fully resorbed in the body. To take advantage of the antimicrobial properties of nMgO for medical use, it is necessary to determine the minimal inhibitory, bactericidal and fungicidal concentrations (MIC, MBC and MFC) of nMgO against prevalent infectious bacteria and yeasts. The objective of this study was to use consistent methods and conditions to reveal and directly compare the efficacy of nMgO against nine prevalent pathogenic microorganisms, including two gram-negative bacteria, three gram-positive bacteria with drug-resistant strains, and four yeasts with drug-resistant strains. The MIC of nMgO varied from 0.5 mg/mL to 1.2 mg/mL and the minimal lethal concentration (MLC) of nMgO at 90% killing varied from 0.7 mg/mL to 1.4 mg/mL against different pathogenic bacteria and yeasts. The most potent concentrations (MPC) of nMgO were 1.4 and/or 1.6 mg/mL, depending on the type of bacteria and yeasts tested. As the concentration of nMgO increased, the adhesion of bacteria and yeasts decreased. Moreover, S. epidermidis biofilm was disrupted at 1.6 mg/mL of nMgO. E. coli and some yeasts showed membrane damage after cultured with ≥0.5 mg/mL nMgO. Overall, nMgO killed both planktonic bacteria and disrupted nascent biofilms, suggesting new antimicrobial mechanisms of nMgO. Production of reactive oxygen species (ROS), Ca

Indexed as

Metal NanoparticlesAnti-Infective AgentsBacteriaBiofilmsDose-Response Relationship, DrugDrug Resistance, MicrobialMagnesium OxideMicrobial Sensitivity TestsYeastsAnti-Infective AgentsMagnesium Oxide

Identifiers

PMID30389984
PMCPMC6214931
OpenAlexW2899407247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.